Cell kinetics of human brain tumors: In vivo study with bromodeoxyuridine and flow cytometry

Marco Danova, Alberto Riccardi, Paolo Gaetani, George D. Wilson, Giuliano Mazzini, Silvia Brugnatelli, Roberto Buttini, Giorgio Butti, Giovanni Ucci, Pietro Paoletti, Edoardo Ascari

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Bromodeoxyuridine (BUDR) is a thymidine analog which is incorporated into the DNA of proliferating cells. Since the dose of BUDR needed to label cells is not toxic, cell labelling can be accomplished in vivo, by infusing the substance in patients. A monoclonal antibody against BUDR is then used to identify BUDR-labelled cells. The same cell population can also be stained for DNA content with propidium iodide (PI). Using bivariate flow cytometry (FCM) for measurements, both the percentage of BUDR-labelled cells and their total DNA content can be evaluated. This technique allows one to obtain the labelling index (LI) and the DNA synthesis time (TS). The potential doubling time (Tpot) and the fractional turnover rate (FTR) can be mathematically derived, so that a complete picture of tumor growth can be obtained. Our aim was to ascertain whether this method is clinically applicable and whether the kinetic values obtained are reliable. We studied 22 patients with benign and malignant brain tumors, and observed no immediate toxicity from BUDR administration. The BUDRLI obtained ranged from 0.9% to 3.9% (median: 2.0%) in meningiomas and from 3.8% to 7.6% (median: 6.3%) in malignant gliomas (Pš0.01). The fraction of S-phase cells determined with the BUDR FCM technique was statistically similar to that found by single DNA flow cytometric analysis performed on duplicate samples of both benign and malignant brain tumors. The TS obtained in malignant gliomas ranged from 10.5 to 227 h (median: 12.8). The calculated Tpot ranged from 7.6 to 26.8 days (median: 11.6), and the calculated FTR ranged from 3.7 to 13.1 cells/100 cells/day (median: 8.8). These data suggest that in vivo BUDR infusion coupled with FCM can be performed in clinical settings, and it is reliable and can easily be used for kinetic studies in clinical trials aimed at evaluating the prognostic relevance of proliferative parameters and in planning tumor treatment.

Original languageEnglish
Pages (from-to)873-880
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume24
Issue number5
DOIs
Publication statusPublished - 1988

Fingerprint

Bromodeoxyuridine
Brain Neoplasms
Flow Cytometry
DNA
Glioma
Propidium
Poisons
Meningioma
S Phase
Thymidine
Neoplasms
Monoclonal Antibodies
Clinical Trials
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Cell kinetics of human brain tumors : In vivo study with bromodeoxyuridine and flow cytometry. / Danova, Marco; Riccardi, Alberto; Gaetani, Paolo; Wilson, George D.; Mazzini, Giuliano; Brugnatelli, Silvia; Buttini, Roberto; Butti, Giorgio; Ucci, Giovanni; Paoletti, Pietro; Ascari, Edoardo.

In: European Journal of Cancer and Clinical Oncology, Vol. 24, No. 5, 1988, p. 873-880.

Research output: Contribution to journalArticle

Danova, Marco ; Riccardi, Alberto ; Gaetani, Paolo ; Wilson, George D. ; Mazzini, Giuliano ; Brugnatelli, Silvia ; Buttini, Roberto ; Butti, Giorgio ; Ucci, Giovanni ; Paoletti, Pietro ; Ascari, Edoardo. / Cell kinetics of human brain tumors : In vivo study with bromodeoxyuridine and flow cytometry. In: European Journal of Cancer and Clinical Oncology. 1988 ; Vol. 24, No. 5. pp. 873-880.
@article{8c1a4b659eab44269b03bb748fa4377e,
title = "Cell kinetics of human brain tumors: In vivo study with bromodeoxyuridine and flow cytometry",
abstract = "Bromodeoxyuridine (BUDR) is a thymidine analog which is incorporated into the DNA of proliferating cells. Since the dose of BUDR needed to label cells is not toxic, cell labelling can be accomplished in vivo, by infusing the substance in patients. A monoclonal antibody against BUDR is then used to identify BUDR-labelled cells. The same cell population can also be stained for DNA content with propidium iodide (PI). Using bivariate flow cytometry (FCM) for measurements, both the percentage of BUDR-labelled cells and their total DNA content can be evaluated. This technique allows one to obtain the labelling index (LI) and the DNA synthesis time (TS). The potential doubling time (Tpot) and the fractional turnover rate (FTR) can be mathematically derived, so that a complete picture of tumor growth can be obtained. Our aim was to ascertain whether this method is clinically applicable and whether the kinetic values obtained are reliable. We studied 22 patients with benign and malignant brain tumors, and observed no immediate toxicity from BUDR administration. The BUDRLI obtained ranged from 0.9{\%} to 3.9{\%} (median: 2.0{\%}) in meningiomas and from 3.8{\%} to 7.6{\%} (median: 6.3{\%}) in malignant gliomas (Pš0.01). The fraction of S-phase cells determined with the BUDR FCM technique was statistically similar to that found by single DNA flow cytometric analysis performed on duplicate samples of both benign and malignant brain tumors. The TS obtained in malignant gliomas ranged from 10.5 to 227 h (median: 12.8). The calculated Tpot ranged from 7.6 to 26.8 days (median: 11.6), and the calculated FTR ranged from 3.7 to 13.1 cells/100 cells/day (median: 8.8). These data suggest that in vivo BUDR infusion coupled with FCM can be performed in clinical settings, and it is reliable and can easily be used for kinetic studies in clinical trials aimed at evaluating the prognostic relevance of proliferative parameters and in planning tumor treatment.",
author = "Marco Danova and Alberto Riccardi and Paolo Gaetani and Wilson, {George D.} and Giuliano Mazzini and Silvia Brugnatelli and Roberto Buttini and Giorgio Butti and Giovanni Ucci and Pietro Paoletti and Edoardo Ascari",
year = "1988",
doi = "10.1016/0277-5379(88)90196-4",
language = "English",
volume = "24",
pages = "873--880",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Cell kinetics of human brain tumors

T2 - In vivo study with bromodeoxyuridine and flow cytometry

AU - Danova, Marco

AU - Riccardi, Alberto

AU - Gaetani, Paolo

AU - Wilson, George D.

AU - Mazzini, Giuliano

AU - Brugnatelli, Silvia

AU - Buttini, Roberto

AU - Butti, Giorgio

AU - Ucci, Giovanni

AU - Paoletti, Pietro

AU - Ascari, Edoardo

PY - 1988

Y1 - 1988

N2 - Bromodeoxyuridine (BUDR) is a thymidine analog which is incorporated into the DNA of proliferating cells. Since the dose of BUDR needed to label cells is not toxic, cell labelling can be accomplished in vivo, by infusing the substance in patients. A monoclonal antibody against BUDR is then used to identify BUDR-labelled cells. The same cell population can also be stained for DNA content with propidium iodide (PI). Using bivariate flow cytometry (FCM) for measurements, both the percentage of BUDR-labelled cells and their total DNA content can be evaluated. This technique allows one to obtain the labelling index (LI) and the DNA synthesis time (TS). The potential doubling time (Tpot) and the fractional turnover rate (FTR) can be mathematically derived, so that a complete picture of tumor growth can be obtained. Our aim was to ascertain whether this method is clinically applicable and whether the kinetic values obtained are reliable. We studied 22 patients with benign and malignant brain tumors, and observed no immediate toxicity from BUDR administration. The BUDRLI obtained ranged from 0.9% to 3.9% (median: 2.0%) in meningiomas and from 3.8% to 7.6% (median: 6.3%) in malignant gliomas (Pš0.01). The fraction of S-phase cells determined with the BUDR FCM technique was statistically similar to that found by single DNA flow cytometric analysis performed on duplicate samples of both benign and malignant brain tumors. The TS obtained in malignant gliomas ranged from 10.5 to 227 h (median: 12.8). The calculated Tpot ranged from 7.6 to 26.8 days (median: 11.6), and the calculated FTR ranged from 3.7 to 13.1 cells/100 cells/day (median: 8.8). These data suggest that in vivo BUDR infusion coupled with FCM can be performed in clinical settings, and it is reliable and can easily be used for kinetic studies in clinical trials aimed at evaluating the prognostic relevance of proliferative parameters and in planning tumor treatment.

AB - Bromodeoxyuridine (BUDR) is a thymidine analog which is incorporated into the DNA of proliferating cells. Since the dose of BUDR needed to label cells is not toxic, cell labelling can be accomplished in vivo, by infusing the substance in patients. A monoclonal antibody against BUDR is then used to identify BUDR-labelled cells. The same cell population can also be stained for DNA content with propidium iodide (PI). Using bivariate flow cytometry (FCM) for measurements, both the percentage of BUDR-labelled cells and their total DNA content can be evaluated. This technique allows one to obtain the labelling index (LI) and the DNA synthesis time (TS). The potential doubling time (Tpot) and the fractional turnover rate (FTR) can be mathematically derived, so that a complete picture of tumor growth can be obtained. Our aim was to ascertain whether this method is clinically applicable and whether the kinetic values obtained are reliable. We studied 22 patients with benign and malignant brain tumors, and observed no immediate toxicity from BUDR administration. The BUDRLI obtained ranged from 0.9% to 3.9% (median: 2.0%) in meningiomas and from 3.8% to 7.6% (median: 6.3%) in malignant gliomas (Pš0.01). The fraction of S-phase cells determined with the BUDR FCM technique was statistically similar to that found by single DNA flow cytometric analysis performed on duplicate samples of both benign and malignant brain tumors. The TS obtained in malignant gliomas ranged from 10.5 to 227 h (median: 12.8). The calculated Tpot ranged from 7.6 to 26.8 days (median: 11.6), and the calculated FTR ranged from 3.7 to 13.1 cells/100 cells/day (median: 8.8). These data suggest that in vivo BUDR infusion coupled with FCM can be performed in clinical settings, and it is reliable and can easily be used for kinetic studies in clinical trials aimed at evaluating the prognostic relevance of proliferative parameters and in planning tumor treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023937038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023937038&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(88)90196-4

DO - 10.1016/0277-5379(88)90196-4

M3 - Article

C2 - 3169092

AN - SCOPUS:0023937038

VL - 24

SP - 873

EP - 880

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -